ANL (Adlai Nortye) Dividends per Share: $0.00 (TTM As of Dec. 2025)


What is Adlai Nortye Dividends per Share?

Adlai Nortye ANL -4.31% Dividends per Share is $0.00 as of Dec. 2025. The stock has 7 warning signs investors should review.

Adlai Nortye's dividends per share for the six months ended in Dec. 2025 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2025 was 0.00. As of today, Adlai Nortye's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Adlai Nortye  (NAS:ANL) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Adlai Nortye's Dividend Payout Ratio for the quarter that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2025 )/ EPS without NRI (Q: Dec. 2025 )
=0/ -0.537
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Dividends per Share Related Terms

Adlai Nortye Dividends per Share Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Dividends per Share Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Dividends per Share
0.00 0.00 0.00 0.00 0.00

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Dividends per Share Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANL vs OMER, PRME, DNA: Dividends per Share Comparison

For the Biotechnology subindustry, Adlai Nortye's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Dividend Yield % falls into.


Adlai Nortye Dividends per Share Calculation

Dividends paid to per common share.

Frequently Asked Questions Learn more about Dividends per Share →
What does a Dividends per Share of $0.00 mean?
Adlai Nortye (ANL) has a Dividends per Share of $0.00 as of Dec. 2025. Dividends per share represents the per-share amount paid as dividends. View historical data on Adlai Nortye and its competitors.
Is Adlai Nortye's Dividends per Share too high?
Adlai Nortye's current Dividends per Share is $0.00.
How does Adlai Nortye's Dividends per Share compare to OMER and PRME?
Adlai Nortye's Dividends per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Dividends per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Dividends per Share of $0.00. The current Dividends per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Dividends per Share is $0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.